Patients with chronic obstructive pulmonary disease (COPD) face a significant cardiovascular burden both before and after diagnosis. Analyses presented at the European Respiratory Society (ERS) ...

Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...

Biological therapy was associated with significant changes in lung structure and, by extension, improved lung function in ...

High-dose fluticasone increases sputum bacterial load in severe COPD; ICS withdrawal is poorly tolerated, highlighting ...

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

While treatment with benralizumab showed numerical improvement over placebo for the primary endpoint, the result was not statistically significant. A phase 3 trial evaluating benralizumab for the ...

A new study published in The American Journal of Medicine found tirzepatide, which is prescribed for diabetes and weight ...

The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations over 52 weeks by a relative 15.4% compared with placebo atop standard care (annualized rate 1.11 vs 1.31, P =0.049), ...

Samay founder and CEO Dr. Maria Artunduaga says things changed pretty quickly for her startup after winning the MedTech ...

Previous non-experimental studies suggest an association between paracetamol exposure in the first year of life and subsequent asthma and eczema developing in childhood; however, randomised trials are ...

C hronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition—primarily chronic bronchitis and emphysema—characterised by persistent respiratory symptoms and airflow limitation.